Cytokine plasma levels: Reliable predictors for radiation pneumonitis?

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Rübe, Claudia E ^a   Palm, Jan ^a   Erren, Michael ^b   Fleckenstein, Jochen ^a   König, Jochem ^c   Remberger, Klaus ^a   Rübe, Christian ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOKINE; ETOPOSIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NAVELBINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIATION PNEUMONIA; RELIABILITY; TREATMENT RESPONSE; TUMOR BIOPSY; BLOOD; LUNG TUMOR; RADIOTHERAPY;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; RADIATION PNEUMONITIS; RADIOTHERAPY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 51649099327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002898     Document Type: Article

References (69)

1. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA (2006) Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 8: 195-202.
2. Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, et al. (2008) Effect of preoperative chemoradiation in addition lo preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9: 636-648.
3. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, et al. (2001) Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radial Oncol Biol Phys 49: 649-655.
4. Wang JY, Chen KY, Wang JT, Chen JH, Lin JW, et al. (2002) Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys 54: 735-741.
5. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI (2007) Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radial Oncol Biol Phys 67: 410-416.
6. Trott KR, Herrmann T, Kasper M (2004) Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 58: 463-469.
7. Rube CE, Rodemann HP, Rube C.(2004) [The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance]. Strablenther Onkol 180: 541-549.
8. Tsoutsou PG, Koukourakis MI (2006) Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66: 1281-1293.
9. Yang K, Palm J, Konig J, Seeland U, Rosenkranz S, el al. (2007) Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury. Int J Radiat Biol 83: 665-676.
10. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109.
11. Rube CE, Uthe D, Schmid KW, Richter KD, Wessel J, et al. (2000) Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys 47: 1033-1042.
12. Rube CE, Uthe D, Wilfert F, Ludwig D, Yang K, el al. (2005) The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Int J Radiat Oncol Biol Phys 61: 1482-1492.
13. Rube CE, Wilfert F, Uthe D, Konig J, Liu L, et al. (2004) Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol 72: 231-241.
14. Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, et al. (2002) Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 64: 177-187.
15. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, et al. (1998) Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 11: 1029-1035.
16. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL (1997) Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 37: 253-258.
17. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, et al. (2001) Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 19: 3758-3765.
18. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, et al. (2003) Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 56; 988-995.
19. Arpin D, Perol D, Blay JY, Falchero L. Claude L, et al. (2005) Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23: 8748-8756.
20. Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, et al. (2005) Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys 62: 260-266.
21. Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, et al. (2001) Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 49: 641-648.
22. Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, et al. (2901) Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50: 899-906.
23. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
24. Rube CE, van Valen F, Wilfert F, Palm J, Schuck A, et al. (2003) Ewing's sarcoma and peripheral primitive neuroectodermal tumor cells produce large quantities of bioactive tumor necrosis factor-alpha (TNF-alpha) after radiation exposure. Int J Radiat Oncol Biol Phys 56: 1414-1425.
25. Schuster N, Krieglstein K (2002) Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res 307: 1-14.
26. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
27. Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94: 230-234.
28. Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775: 163-180.
29. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL (2001) Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 276: 46707-46713.
30. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
31. Goumans MJ, Lebrin F, Valdimarsdottir G (2003) Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 13: 301-307.
32. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, et al. (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A 87: 1486-1490.
33. Caligiuri MAaL, M T, eds (2007) Cytokines in the genesis and treatment of cancer. Totowa, New Jersey: Humana Press Inc. pp 482.
34. Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2: 862-871.
35. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86: 1712-1719.
36. Kong FM, Washington MK, Jirtle RL, Anscher MS (1996) Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 16: 47-59.
37. Nokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, et al. 2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20: 4191-4198.
38. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, et al. (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J. Clin Oncol 20: 3454-3460.
39. Nestle U, Nieder C, Walter K, Abel U, Ukena D, et al. (2000) A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 48: 95-103.
40. Pantsulaia I, Trofimov S, Kalichman L, Kobyliansky E, Livshits G (2004) The contribution of familial reserablance to variation in laboratory leads of tissue inhibitors of metalloproteinases and transforming growth factor-beta1. Calcif Tissue Int 74: 47-54.
41. Asakura S, Kato H, Fujino S, Konishi T, Tezuka N, et al. (1999) Role of transforming growth factor-beta1 and decorin in development of central fibrosis in pulmonary adenocarcinoma. Hum Pathol 30: 195-198.
42. Asselin-Paturel C, Echchakir H, Carayol G, Gay T, Opolon P, et al. (1998) Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77: 7-12.
43. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 31: 1049-1091.
44. Therasse P, Fisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42: 1031-1039.
45. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, el al. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21: 2574-2582.
46. Vujaskovic Z, Groen HJ (2000) TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76: 511-516.
47. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, et al. (2004) Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58: 1378-1387.
48. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ (2004) Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71: 183-189.
49. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759.
50. Chang KT, Huang CY, Tsai CM, Chiu CH, Lok YY (2005) Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. Am J Physiol Lung Cell Mol Physiol 289: 1438-445.
51. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, et al. (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858.
52. Haura EB, Livingston S, Coppola D (2006) Autocrine interleukin-6/ interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer 7: 273-275.
53. Song L, Turkson J, Karras JG, Jove R, Haura EB (2003) Activation of Staff by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165.
54. To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, et al. (2002) A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol 27: 220-226.
55. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, et al. (2004) Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53: 786-792.
56. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC (2006) Autocrine II-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25: 4300-4309.
57. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, et al. (2006) Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology 70: 115-125.
58. Kayacan O, Karnak D, Beder S, Gullu E, Tutkak H, et al. (2006) Impact of TNF-alpha and II-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 29: 328-335.
59. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, et al. (2005) Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22: 353-358.
60. Anumanthan G, Halder SK, Osada H, Takahashi T, Massion PP, et al. (2005) Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells. Br J Cancer 03: 1157-1167.
61. Bachman KE, Park BH (2005) Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 17: 49-54.
62. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
63. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, et al. (2006) Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immumol 176: 5637-5643.
64. Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457.
65. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, et al. (2004) Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999.
66. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, et al. (2001) Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864.
67. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, et al. (1998) p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4: 1499-1506.
68. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, et al. (2001) Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964-971.
69. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, et al. (2003) Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 39: 454-161.